ClinicalTrials.Veeva

Find clinical trials for Lymphoma in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Birmingham, AL, USA:

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment....

Active, not recruiting
Follicular Lymphoma
Mantle-cell Lymphoma
Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule
Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule

Phase 1

Juno Therapeutics

Birmingham, Alabama, United States and 13 other locations

dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...

Enrolling
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

Phase 1, Phase 2

BeiGene
BeiGene

Birmingham, Alabama, United States and 95 other locations

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...

Enrolling
EBV Associated Lymphoma
EBV Related Non-Hodgkin's Lymphoma
Drug: Nanatinostat in combination with valganciclovir

Phase 2

Viracta Therapeutics

Birmingham, Alabama, United States and 94 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: bleomycin

Phase 3

Takeda
Takeda

Birmingham, Alabama, United States and 215 other locations

in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton...

Active, not recruiting
Lymphoma
Drug: Parsaclisib

Phase 2

Incyte
Incyte

Birmingham, Alabama, United States and 85 other locations

T cells, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma.The study will consist of 2 parts: dose-escalation (Part A) and...

Active, not recruiting
Agressive Lymphoma
Diffuse-large B-cell Lymphoma (DLBCL)
Biological: CC-97540

Phase 1

Juno Therapeutics

Birmingham, Alabama, United States and 13 other locations

pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas...

Enrolling
Other CD8+/NK Cell Driven Lymphoma Not Listed Above
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Drug: DR-01

Phase 1, Phase 2

Dren Bio

Birmingham, Alabama, United States and 19 other locations

regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosin...

Active, not recruiting
Lymphoma
Drug: Parsaclisib

Phase 2

Incyte
Incyte

Birmingham, Alabama, United States and 102 other locations

of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabin...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Drug: Cyclophosphamide
Genetic: CB-010

Phase 1

Caribou Biosciences

Birmingham, Alabama, United States and 28 other locations

trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary object...

Enrolling
Non Hodgkin Lymphoma
Drug: Rituximab
Drug: Cyclophosphamide

Phase 1, Phase 2

Artiva Biotherapeutics

Birmingham, Alabama, United States and 20 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems